This page contains a Flash digital edition of a book.
Don’t see the need for another NSAID?


is different. No other NSAID


combines all these features.


• Peak plasma levels achieved within 90 minutes of dosing1 • Same dose rate for all label claims (osteoarthritis, soft-tissue and orthopedic surgery)2


• Once-daily dosing, with no age restriction2 • Developed solely for veterinary use • Highly COX-2 selective and COX-1 sparing at therapeutic dose3, *


• In multi-center field studies PREVICOX Chewable Tablets were rated convenient to administer (97.2%) by owners2


*No clinical relevance has been demonstrated.


See for yourself – try PREVICOX (firocoxib) the next time your patient needs an NSAID.


®


For more information, please contact your Merial Sales Representative or visit www.PREVICOX.com


Important Safety Information: As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney or liver side effects. These are usually mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for pets on any medication, including PREVICOX. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. Refer to the prescribing information for complete details or visit www.PREVICOX.com.


1Data on file at Merial, PR&D 84101. 2 PREVICOX Prescribing Information.


3


McCann ME, Anderson DR, Zhang D, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res 2004; 65(4):503-512.


®PREVICOX is a registered trademark of Merial. ©2010 Merial Limited, Duluth, GA. All rights reserved. PVX10NADIFFTRADE2.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103